Gliatilin - choline alfoscerate

International Non-Proprietary Name (INN): choline alfostserat.

Pharmacological group: "nootropic agent"
ATC code: N07AH02

Product form:

Ampoules 1000mg / 4ml, 3 capsules per pack
Capsules 400mg, 14 capsules per pack.

Gliatilin in the Russian market since 1994. Included:

• Gliatilin is in the list of vital and essential medicines.
• The standards of specialized medical care for neurological diseases (cerebral infarction, spinal muscular atrophy).
• The federal leadership on drug therapy (neurology, psychiatry).
• Gliatilin is a donor of acetylcholine (a neurotransmitter of cholinergic structures of the central nervous system) and phosphatidylcholine (the main structural component of cell membranes and intracellular organelles).

Thus, gliatilin improves the transmission of signals from neuron to neuron, stabilizes the receptor field of neuronal membranes and prevents the destruction of brain tissue in critical situations, activates the recovery of neurons and neuronal synapses in the post-critical period. Clinically gliatilin provides a wake-up action (recovery of consciousness), improvement of cognitive, behavioral, emotional, motor functions.

Gliatilin unique feature is its ability to penetrate the blood-brain barrier at a high concentration (40.5% of the plasma concentration) and replenish endogenous acetylcholine deficiency even in critical situations (acute hypoxic-ischemic brain damage and toxicity) as choline, acetylcholine becomes through a biochemical reaction of acetylation. Thus, gliatilin has a strong central action and, in practice, has no peripheral (bradycardia, bronchospasm, salivation), characteristic of generic drugs.

Gliatilin is indicated for:

Stroke (ischemic and hemorrhagic in the acute and recovery period)
Traumatic brain injury of different severity
Cognitive disorders of various origins.

Gliatilin has a high level evidence base.